Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
NCT05004129
Recruiting
This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.
Gender:
All
Ages:
Between 6 years and 45 years
Trial Updated:
11/05/2023
Locations: University of Utah Clinical Neurosciences Center, Salt Lake City, Utah
Conditions: Congenital Myotonic Dystrophy
Register for Updates
Youth Partners in Care for Suicide Prevention
NCT05304065
Recruiting
This randomized comparative effectiveness trial will compare two evidence-based approaches to emergency care for youth ages 15-24 who present to the Emergency Department (ED) with suicidal ideation or behavior. OUtcomes will be monitored at baseline and at 3, 6 & 12 month follow-up assessments.
Gender:
All
Ages:
Between 15 years and 24 years
Trial Updated:
11/03/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Suicide and Self-harm
Register for Updates
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
NCT04972110
Recruiting
The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 (camonsertib) in combination with niraparib or olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: Participating Site # 1013, Salt Lake City, Utah
Conditions: Advanced Solid Tumor, Adult
Register for Updates
A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
NCT05101317
Recruiting
This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
11/01/2023
Locations: Physicians' Research Options, LLC- Corner Canyon Clinic, Draper, Utah
Conditions: Endometriosis
Register for Updates
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
NCT03801434
Recruiting
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells, Blasts Under 20 Percent of Bone Marrow Nucleated Cells, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Eosinophilia, Hepatomegaly, Hypereosinophilic Syndrome, JAK2 Gene Mutation, Splenomegaly, TEL-JAK2 Fusion Protein Expression
Register for Updates
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
NCT05663502
Recruiting
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma, Lymphoma, Malignant Solid Neoplasm, Multicentric Castleman Disease, Plasmablastic Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lymphoma, Recurrent Plasmablastic Lymphoma, Transplant-Related Kaposi Sarcoma
Register for Updates
Long-term COVID and Rehabilitation
NCT05373043
Recruiting
The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19. The investigators expected outcomes will have an important positive impact because they will provide scientifically sound recommendations for rehabilitation to improve vascular endothelial function... Read More
Gender:
All
Ages:
All
Trial Updated:
10/30/2023
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: Long-COVID
Register for Updates
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
All
Ages:
Between 28 days and 18 years
Trial Updated:
10/30/2023
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02810704
Recruiting
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/30/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Pulmonary Embolism, Venous Thrombosis
Register for Updates
Progression of Early Atrophic Lesions
NCT05959005
Recruiting
Early atrophic age-related macular degeneration (AMD) represents an important time window in the course of so far untreatable atrophic AMD, as patients typically experience only some degree of visual dysfunction, while being at significant risk for marked further loss of vision. To allow the precise evaluation of upcoming therapeutic interventions, a better understanding of the manifestation and variable disease progression is needed. This project aims to investigate refined tools to detect and... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
10/28/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Age-Related Macular Degeneration
Register for Updates
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Register for Updates
Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment
NCT06087991
Recruiting
This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED bupreno... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Opioid Abuse
Register for Updates